Clinical Trial Update: TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r) [Phase 1]

View source ↗

Summary

Phase 1 PK interaction study in healthy volunteers to evaluate how TMC435 interacts with erythromycin and with darunavir/ritonavir, in the Hepatitis C setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ERYTHROMYCIN (ERYTHROMYCIN)
• TMC435
• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED